Ricerc@Sapienza

Purpose: Purpose: a commonly recognized complication of intravitreal steroids is secondary ocular hypertension (OHT). The aim of this retrospective study is to further characterize the effects of sustained-release intravitreal dexamethasone implants (SIDIs) on intraocular pressure (IOP). Specifically, we describe time course, incidence, and pharmacological management of OHT in eyes receiving repeated injections. Methods: Methods: this study included 78 eyes (78 patients) and 154 SIDIs injections over 3 years. Mean age: 67±13.4 SD, 48 males (62%) and 30 females (38%).

The present review focuses on recent clinical trials that analyze the efficacy of
intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD),
such as neuroprotective drugs, and complement inhibitors, also called immunomodulatory or
anti-inflammatory agents. A systematic literature search was performed to identify randomized
controlled trials published prior to January 2019. Patients affected by dry AMD treated with
intravitreal therapeutic agents were included. Changes in the correct visual acuity and reduction in